Daniel E Salazar

Dr. Salazar is an accomplished pharmaceutical research and development executive with significant accomplishments across all phases of development and different therapeutic areas. His core areas of expertise are in translational science, clinical development, clinical pharmacology, pharmacokinetics, biopharmaceutics, pharmacometrics molecular pharmacology, pharmacogenomics, outsourcing, regulatory strategy, biomarkers, companion diagnostics, and digital health. He has more than 25 years of experience in drug discovery, development, regulatory submissions, and organizational leadership. He has made significant contributions to over 40 IND filings and 9 NDAs including Abilify®, Benicar HCT®, Azor®, Tribenzor®, Welchol®, Effient®, and Sayvasa®. He is currently, Chief Scientific Officer and a member of the Board of Directors of EMS Pharma, the leading pharmaceutical company in Brazil and Latin America. Dr. Salazar is also Vice President Clinical and Regulatory, Brace Pharma Capital, the venture capital company of EMS Pharma located in Rockville, MD. Dr. Salazar is the Acting Chief Technical Officer and a member of the Board of Managers for VERO Biotech. He also is Acting Sr Vice President of Development and Director for Tyrogenex, Inc. Dr. Salazar completed his undergraduate education at Princeton University where he majored in Biology and his Doctor of Pharmaceutical Science from the State University of New York at Buffalo. He has directed over 100 clinical studies investigating dosage form bioequivalence, drug absorption, first administration to man, proof of concept, pharmacokinetics, pharmacodynamics, disease state interactions, and drug-drug interactions. Dr. Salazar is the co-author of 5 book chapters and 80 articles in peer-reviewed journals.